Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder

References

• Horan RF, Austen KF. Systemic mastocytosis: restrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991;96 Suppl:5S–14S.
   Web of Science ®Google Scholar
• Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol/Oncol Clin North Am 2000; 14: 579–623
   PubMed Web of Science ®Google Scholar
• Castells M, Austen KF. Mastocytosis: mediator related signs and symptoms. Int Arch Allergy Immunol 2002; 127: 147–52
   PubMed Web of Science ®Google Scholar
• Feger F, Ribadeau-Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002; 12: 110–4
   Web of Science ®Google Scholar
• Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 2005; 114: 61–9
   PubMed Web of Science ®Google Scholar
• Austen KF, Boyce JA. Mast cell lineage development and phenotypic regulation. Leuk Res 2001; 25: 511–8
   PubMed Web of Science ®Google Scholar
• Molderings GJ, Kolck U, Scheurlen C, Brüss M, Frieling T, Raithel M, et al. Systemic mast cell disease with gastrointestinal symptoms: a diagnostic questionnaire. Dtsch Med Wochenschr 2006; 131: 2095–100
   PubMed Web of Science ®Google Scholar
• Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1998; 12: 345–55
   Web of Science ®Google Scholar
• Kirshenbaum AS, Metcalfe DD. Growth of human mast cells from bone marrow and peripheral blood-derived CD34 + pluripotent progenitor cells. Methods Mol Biol 2005; 315: 105–11
   Google Scholar
• Wang X, Sam SW, Yip KH, Lau HYA. Functional characterization of human mast cells cultured from adult peripheral blood. Intern Immunopharmacol 2006; 6: 839–47
   PubMed Web of Science ®Google Scholar
• Crosier PS, Ricciardi ST, Hall LR, Vitas MR, Clark SC, Crosier KE. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 1993; 82: 1151–8
   PubMed Web of Science ®Google Scholar
• Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004; 114: 13–9
   PubMed Web of Science ®Google Scholar
• Blechman JM, Lev S, Brizzi MF, Leitner O, Pegoraro L, Givol D, et al. Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. J Biol Chem 1993; 268: 4399–406
   PubMed Web of Science ®Google Scholar
• Broudy VC, Lin NL, Buhring HJ, Komatsu N, Kavangh TJ. Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer. Blood 1998; 91: 898–906
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Pinchasi D, Zhou M, Lax I, Schlessinger J. Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem 1997; 272: 6311–7
   PubMed Web of Science ®Google Scholar
• Ozer O, Anastasi J, Vardiman JW, Godley LA. Identical novel c- KIT transcripts in two patients. Blood 2004; 104: 552A–552A [ abstract].
   Web of Science ®Google Scholar
• Hayashi S, Kunisada T, Ogawa M, Yamaguchi K, Nishikawa S. Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. Nucleic Acids Res 1991; 19: 1267–71
   PubMed Web of Science ®Google Scholar
• Piao X, Curtis JE, Minkin S, Minden MD, Bernstein A. Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. Blood 1994; 83: 476–81
   PubMed Web of Science ®Google Scholar
• Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K. Alterations of the c- kit gene in testicular germ cell tumors. Cancer Sci 2003; 94: 486–91
   PubMed Web of Science ®Google Scholar
• Theou N, Tabone S, Saffroy R, Le Cesne A, Julie C, Cortez A, et al. High expression of both mutant and wild type alleles of c-kit in gastrointestinal stromal tumors. Biochimica Biophysica Acta 2004; 1688: 250–6
   PubMed Web of Science ®Google Scholar
• Caruana G, Cambareri AC, Ashman LK. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 1999; 18: 5573–81
   PubMed Web of Science ®Google Scholar
• Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge S, Ashman LK, et al. Src family kinases are involved in the differential signaling from two splice forms of c-kit. J Biol Chem 2003; 278: 9159–66
   PubMed Web of Science ®Google Scholar
• Andersson J, Sjögren H, Meis-Kindblom JM, Stenman G, Aman P, Kindblom LG. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160: 15–22
   PubMed Web of Science ®Google Scholar
• Fletcher JA, Fletcher CDM, Rubin BP, Ashman LK, Corless CL, Heinrich MC. KIT gene mutations in gastrointestinal stromal tumors. Am J Pathol 2002; 161: 737–8
   PubMed Web of Science ®Google Scholar
• Lasota J, Kopczynski J, Majidi M, Miettinen M. Apparent KIT Ser 715 deletion in GIST mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript. Am J Pathol 2002; 161: 739–41
   PubMed Web of Science ®Google Scholar
• Lev S, Yarden Y, Givol D. A recombinant ectodomain of the receptor for the stem cell factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses. J Biol Chem 1992; 267: 10866–73
   PubMed Web of Science ®Google Scholar
• Reber L, da Silva CA, Frossard N. Stem cell factor and its receptor c-kit as targets for inflammatory diseases. Eur J Pharmacol 2006; 533: 327–40
   PubMed Web of Science ®Google Scholar
• Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560G kit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816Vkit is resistant. Mol Cancer Ther 2002; 1: 1115–24
   PubMed Web of Science ®Google Scholar
• Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, et al. Structural basis for the autoinhibition and ST571 inhibition of c-kit tyrosine kinase. J Biol Chem 2004; 279: 31655–63
   PubMed Web of Science ®Google Scholar
• Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, et al. c-Kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995; 91: 661–3
   PubMed Web of Science ®Google Scholar
• Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, et al. c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukemia. Br J Haematol 1999; 105: 894–900
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci 2005; 102: 1104–9
   PubMed Web of Science ®Google Scholar
• Kohl TM, Schnittger S, Ellwart JW, Hiddemann W, Spiekermann K. KIT exon 8 mutations associated with core-binding factor (CBF)- acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005; 105: 3319–21
   PubMed Web of Science ®Google Scholar
• Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia 2005; 19: 1673–5
   PubMed Web of Science ®Google Scholar
• Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib. Blood 2004; 103: 3222–5
   PubMed Web of Science ®Google Scholar
• Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR. Mutation analysis of c-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357–64
   PubMed Web of Science ®Google Scholar
• Roskoski R. Signaling by Kit protein-tyrosine kinase: the stem cell factor receptor. Biochem Biophys Res Commun 2005; 337: 1–13
   PubMed Web of Science ®Google Scholar
• Tarn C, Merkel E, Canutescu AA, Shen W, Skorobogatko Y, Heslin MJ, et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 2005; 11: 3668–76
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, et al. Association of KIT Exon 9 mutations with nongastric primary site and aggressive behaviour: KIT mutation analysis and clincal correlates of 120 gastroentestinal stromal tumors. Clin Cancer Res 2003; 9: 3329–37
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118–21
   PubMed Web of Science ®Google Scholar
• Sundstrom M, Vliagoftis H, Karlberg P, Butterfield JH, Nilsson K, Metcalfe DD, et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 2003; 108: 89–97
   PubMed Web of Science ®Google Scholar
• Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ, Mechtersheimer G. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 2005; 58: 634–9
   PubMed Web of Science ®Google Scholar
• Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995; 85: 790–8
   PubMed Web of Science ®Google Scholar
• Chu SC, Tang JL, Li CC. Dasatinib in chronic myelogenous leukemia. N Engl J Med 2006; 355: 1062–3
   PubMed Web of Science ®Google Scholar
• Paronetto MP, Farini D, Sammarco I, Maturo G, Vespasiani G, Geremia R, et al. Expression of a truncated form of the c-kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am J Pathol 2004; 164: 1243–51
   PubMed Web of Science ®Google Scholar
• Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603–25
   PubMed Web of Science ®Google Scholar
• Jakate S, Demeo M, John R, Tobin M, Keshavarzian A. Mastocytic enterocolitis. Arch Pathol Lab Med 2006; 130: 362–7
   PubMed Web of Science ®Google Scholar